Bitcoin price today: dips below $112k, near 6-wk low despite Fed cut bets
Sensei Biotherapeutics , Inc. (NASDAQ:SNSE), a biopharmaceutical company currently trading at $0.34 with a market capitalization of $8.46 million, has announced a one-for-twenty reverse stock split of its common stock, set to take effect at the close of business on Monday, June 16, 2025. According to InvestingPro analysis, while the company maintains strong liquidity with more cash than debt, it faces challenges with rapid cash burn and profitability concerns. The decision, which also includes a reduction of the total number of authorized shares from 250 million to 12.5 million, was approved by the company’s board following authorization from stockholders at the annual meeting on May 21, 2025.
This strategic move will consolidate every twenty shares of issued and outstanding common stock into one share. It aims to increase the market price per share, making the stock more attractive to a broader range of investors. The company’s current financial health score from InvestingPro stands at FAIR, with a notably strong current ratio of 6.82x, indicating solid short-term financial stability. The reverse stock split will proportionally adjust the per-share exercise price and the number of shares issuable upon the exercise or vesting of all stock options, restricted stock unit awards, and warrants outstanding immediately before the amendment takes effect. Consequently, there will be a proportional decrease in the number of shares reserved for issuance under the company’s equity compensation plans.
Stockholders who would otherwise hold a fractional share will receive a cash payment instead, ensuring that no fractional shares are issued. The reverse stock split is intended to affect all stockholders equally and will not alter any stockholder’s percentage ownership interests in Sensei Biotherapeutics, except for minor changes due to the elimination of fractional shares.
Trading on a split-adjusted basis on The Nasdaq Capital Market will commence on Tuesday, June 17, 2025, under the new CUSIP number 81728A207. For investors seeking deeper insights, InvestingPro offers 5 additional key tips about SNSE’s financial position and growth prospects, along with comprehensive valuation metrics and peer comparison tools. Further details of the reverse stock split are outlined in the Amendment filed with the SEC, which is incorporated by reference into this article and is based on a press release statement.
In other recent news, Sensei Biotherapeutics has announced a 1-for-20 reverse stock split, which will reduce the number of outstanding shares from approximately 25.2 million to 1.3 million. This move aims to comply with Nasdaq’s minimum bid price requirement and was approved by stockholders at the company’s annual meeting. The reverse stock split will affect stock options, restricted stock unit awards, and warrants, with Equiniti Trust Company serving as the exchange agent. In addition, H.C. Wainwright has assumed a Buy rating on Sensei Biotherapeutics, highlighting its innovative approach to developing immune checkpoint inhibitors. The firm’s price target for the stock is set at $5.00.
The company also reported promising preliminary results from its Phase 1/2 trial of solnerstotug, showing a 14% overall response rate in patients resistant to PD-(L)1 inhibitors. Notably, a durable complete response was observed in a Merkel Cell Carcinoma patient. Sensei plans to initiate a Phase 2 study in early 2026, focusing on biomarker-based patient selection. These developments reflect the company’s ongoing efforts to advance its cancer therapy pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.